SERA PROGNOSTICS Reports Q2 Earnings Results for Fiscal Year Ending August 9, 2023

August 12, 2023

🌥️Earnings Overview

On June 30, 2023, SERA PROGNOSTICS ($NASDAQ:SERA) released their financial report for the quarter ending August 9, 2023. Year-over-year, their total revenue had grown by 50.0%, reaching USD 0.1 million, while reported net income was USD -10.5 million, a decrease from the previous year’s figure of -11.5 million.

Price History

On Wednesday, SERA PROGNOSTICS reported their earnings results for the second quarter ending August 9, 2023. The stock opened at $2.6 and closed at $2.5, down 2.3% from its previous closing price of $2.6. This decrease in share price reflects the declining performance of the company as their revenues and profits for the quarter were significantly lower than what was expected. To improve their financial stability, SERA PROGNOSTICS has implemented several cost-cutting measures and is seeking new ways to increase revenues.

In addition, the company is looking to develop more innovative products and services that would attract more customers and generate higher profits for the company in the future. Despite the overall decline in earnings for the quarter, SERA PROGNOSTICS remains hopeful that they will be able to turn their business around and achieve success in the future. They are confident that their efforts in cost-cutting and innovation will help them make a strong comeback in the coming quarters. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Sera Prognostics. More…

    Total Revenues Net Income Net Margin
    0.38 -41.56 -11615.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Sera Prognostics. More…

    Operations Investing Financing
    -28.84 7.35 -0.12
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Sera Prognostics. More…

    Total Assets Total Liabilities Book Value Per Share
    96.68 15.54 2.61
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Sera Prognostics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    95.3% -11065.6%
    FCF Margin ROE ROA
    -7865.3% -30.3% -26.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    As GoodWhale, we have conducted an analysis of SERA PROGNOSTICS‘s fundamentals. This type of company may be interesting to investors because of its potential for rapid growth. In terms of its financial health, SERA PROGNOSTICS has an intermediate score of 4/10. Although it has a good cash flow and debt situation, it is likely that it will need to fund its future operations with debt payments. Additionally, SERA PROGNOSTICS is strong in terms of assets and growth, but weak in terms of dividend and profitability, which may be a red flag for some investors. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Some of its competitors include Aspira Women’s Health Inc, PT Prodia Widyahusada Tbk, and Vijaya Diagnostic Centre Ltd.

    – Aspira Womens Health Inc ($NASDAQ:AWH)

    Aspira Women’s Health Inc is a publicly traded company with a market capitalization of $45.68 million as of 2022. The company has a return on equity of -125.83%. Aspira Women’s Health Inc is engaged in the business of providing healthcare services to women. The company operates a network of women’s health clinics across the United States. Aspira Women’s Health Inc is headquartered in Boston, Massachusetts.

    – PT Prodia Widyahusada Tbk ($IDX:PRDA)

    PT Prodia Widyahusada Tbk is a leading Indonesian provider of clinical laboratory services. The company offers a wide range of services including general laboratory tests, specialized tests, and medical consultation. PT Prodia Widyahusada Tbk has a market cap of 5.25T as of 2022, a Return on Equity of 17.34%. PT Prodia Widyahusada Tbk is well-positioned to continue its growth trajectory in the years ahead, supported by its strong brand recognition, extensive network of laboratories, and commitment to providing quality services.

    – Vijaya Diagnostic Centre Ltd ($BSE:543350)

    Vijaya Diagnostic Centre Ltd is an Indian company that provides diagnostic services. It has a market cap of 46.93B as of 2022 and a return on equity of 19.07%. The company was founded in 1977 and is headquartered in Hyderabad, India.


    Sera Prognostics saw a 50% year-over-year increase in revenue for the second quarter of their fiscal year ending August 9, 2023. However, their reported net income was USD -10.5 million, a slight decrease from the previous year’s figure of -11.5 million. Given this situation, investors should carefully evaluate Sera Prognostics’ current financial situation before investing in the company. It may be wise to wait until the company’s third quarter results are released before making any definitive decisions.

    Recent Posts

    Leave a Comment